TransMedics Group, Inc. (TMDX) Return on Equity (ROE): 34.80%
Is TransMedics Group, Inc.’s return on equity (ROE) high or low?
TransMedics Group, Inc.'s return on equity (ROE) of 34.80% is 380% above its 5-year average of -12.45%, near the high end of its 5-year range (-65.16%–40.22%).
As of Saturday, June 20, 2026. 24.89% above its 12-month average of 27.86%.
TMDX Return on Equity (ROE) Chart
TMDX Average Return on Equity (ROE) Chart
TMDX Current vs Average Return on Equity (ROE) Chart
TMDX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
34.80%
RETURN ON EQUITY (ROE) AVG TTM
27.86%
RETURN ON EQUITY (ROE) AVG 3Y
4.54%
RETURN ON EQUITY (ROE) AVG 5Y
-12.45%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.89%
CURRENT VS 3Y AVG
+666.94%
CURRENT VS 5Y AVG
+379.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 34.80% | 27.86% | 4.54% | -12.45% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | -47.65% | -45.75% | -30.11% | -18.95% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 2.46% | -8.94% | -15.72% | 1.14% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | -2.97% | 25.09% | 5.57% | 0.40% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -72.74% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | -6.28% | -2.13% | 6.32% | 9.65% |
| Baxter International Inc. (BAX)vs › | $10.27B | -18.17% | -12.46% | -8.76% | -1.37% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 3.35% | 3.59% | 3.35% | 7.68% |
Return Analysis
ROE
34.8%
ROA
12.0%
TransMedics Group, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for TransMedics Group, Inc. (TMDX)?
- The return on equity (ROE) for TMDX stock is 34.80%.
- Is TransMedics Group, Inc.'s return on equity (ROE) high or low?
- TransMedics Group, Inc.'s return on equity (ROE) of 34.80% is 380% above its 5-year average of -12.45%, near the high end of its 5-year range (-65.16%–40.22%).
- What is the TTM average return on equity (ROE) for TransMedics Group, Inc. (TMDX)?
- The TTM average return on equity (ROE) for TMDX stock is 27.86%.
- What is the 3Y average return on equity (ROE) for TransMedics Group, Inc. (TMDX)?
- The 3Y average return on equity (ROE) for TMDX stock is 4.54%.
- What is the 5Y average return on equity (ROE) for TransMedics Group, Inc. (TMDX)?
- The 5Y average return on equity (ROE) for TMDX stock is -12.45%.
TransMedics Group, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 40.22% |
| 2024-12-31 | 15.51% |
| 2023-12-31 | -18.24% |
| 2022-12-31 | -19.34% |
| 2021-12-31 | -65.16% |
| 2020-12-31 | -27.67% |
| 2019-12-31 | -61.39% |
| 2018-12-31 | 492.35% |
| 2017-12-31 | 12.34% |
| 2016-12-31 | -62.04% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein